Kraig Biocraft Laboratories (KBLB) Common Equity (2010 - 2026)

Kraig Biocraft Laboratories has disclosed Common Equity across 17 years of filings, most recently posting -$6.8 million for Q2 2026.

• In Q2 2026, Common Equity rose 20.32% year-over-year to -$6.8 million; the TTM figure through Jun 2026 stood at -$6.8 million (up 20.32% YoY), while the FY2025 annual figure was -$8.0 million, up 1.85% from the prior year.
• Common Equity came in at -$6.8 million for Q2 2026 at Kraig Biocraft Laboratories, up from -$8.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$3.5 million in Q4 2022 to a low of -$8.5 million in Q1 2025.
• Average Common Equity over 5 years is -$6.1 million, with a median of -$6.2 million recorded in 2024.
• Year-over-year, Common Equity jumped 40.36% in 2022 and slumped 62.05% in 2023.
• Over 5 years, Common Equity stood at -$3.5 million in 2022, then sank by 62.05% to -$5.7 million in 2023, then tumbled by 42.8% to -$8.1 million in 2024, then grew by 1.85% to -$8.0 million in 2025, then increased by 15.6% to -$6.8 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$6.8 million in Q2 2026, -$8.0 million in Q4 2025, and -$8.0 million in Q3 2025.